BioMark Diagnostics Inc. (BMKDF)
USD 0.18
(0.0%)
USD 0.18
(0.0%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 | 649.18 Thousand CAD | -13.65% |
| 2023 | 751.83 Thousand CAD | 12.77% |
| 2022 | 666.68 Thousand CAD | 187.91% |
| 2021 | -758.35 Thousand CAD | -25.73% |
| 2020 | -603.13 Thousand CAD | -2916.6% |
| 2019 | -19.99 Thousand CAD | 45.42% |
| 2018 | -36.63 Thousand CAD | -109.46% |
| 2017 | -17.48 Thousand CAD | -23.75% |
| 2016 | -14.13 Thousand CAD | 92.8% |
| 2015 | -196.23 Thousand CAD | -113.3% |
| 2014 | -92 Thousand CAD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q3 | 670.53 Thousand CAD | 169.03% |
| 2024 Q1 | 464.89 Thousand CAD | -38.16% |
| 2024 Q2 | 249.24 Thousand CAD | -46.39% |
| 2024 Q4 | 649.18 Thousand CAD | -3.18% |
| 2024 FY | 649.18 Thousand CAD | -13.65% |
| 2023 FY | 751.83 Thousand CAD | 12.77% |
| 2023 Q3 | 774.39 Thousand CAD | -6.7% |
| 2023 Q4 | 751.83 Thousand CAD | -2.91% |
| 2023 Q2 | 830.03 Thousand CAD | 34.85% |
| 2023 Q1 | 615.53 Thousand CAD | -7.67% |
| 2022 Q3 | 790.52 Thousand CAD | 400.81% |
| 2022 Q1 | -563.73 Thousand CAD | 25.66% |
| 2022 FY | 666.68 Thousand CAD | 187.91% |
| 2022 Q4 | 666.68 Thousand CAD | -15.67% |
| 2022 Q2 | -262.8 Thousand CAD | 53.38% |
| 2021 Q4 | -758.35 Thousand CAD | -194.56% |
| 2021 FY | -758.35 Thousand CAD | -25.73% |
| 2021 Q1 | -500.16 Thousand CAD | 17.07% |
| 2021 Q3 | -257.45 Thousand CAD | 31.03% |
| 2021 Q2 | -373.27 Thousand CAD | 25.37% |
| 2020 FY | -603.13 Thousand CAD | -2916.6% |
| 2020 Q4 | -603.13 Thousand CAD | -373.11% |
| 2020 Q3 | 220.83 Thousand CAD | 438.25% |
| 2020 Q2 | -65.28 Thousand CAD | 57.92% |
| 2020 Q1 | -155.15 Thousand CAD | -676.0% |
| 2019 Q4 | -19.99 Thousand CAD | -102.11% |
| 2019 FY | -19.99 Thousand CAD | 45.42% |
| 2019 Q3 | 945.82 Thousand CAD | 9.66% |
| 2019 Q2 | 862.52 Thousand CAD | 18.69% |
| 2019 Q1 | 726.7 Thousand CAD | 2083.81% |
| 2018 Q1 | 327.2 Thousand CAD | 1970.9% |
| 2018 FY | -36.63 Thousand CAD | -109.46% |
| 2018 Q4 | -36.63 Thousand CAD | -106.39% |
| 2018 Q3 | 573 Thousand CAD | 54.1% |
| 2018 Q2 | 371.84 Thousand CAD | 13.64% |
| 2017 Q2 | 544.23 Thousand CAD | 28.98% |
| 2017 FY | -17.48 Thousand CAD | -23.75% |
| 2017 Q4 | -17.48 Thousand CAD | -746.92% |
| 2017 Q3 | -2065.00 CAD | -100.38% |
| 2017 Q1 | 421.95 Thousand CAD | 3085.83% |
| 2016 Q2 | 200.53 Thousand CAD | 94.96% |
| 2016 Q1 | 102.85 Thousand CAD | 152.42% |
| 2016 Q3 | 331.71 Thousand CAD | 65.42% |
| 2016 FY | -14.13 Thousand CAD | 92.8% |
| 2016 Q4 | -14.13 Thousand CAD | -104.26% |
| 2015 Q4 | -196.23 Thousand CAD | -3740.97% |
| 2015 Q1 | 92 Thousand CAD | 0.0% |
| 2015 Q2 | -1.00 CAD | -100.0% |
| 2015 Q3 | -5109.00 CAD | -510800.0% |
| 2015 FY | -196.23 Thousand CAD | -113.3% |
| 2014 FY | -92 Thousand CAD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| American Bio Medica Corporation | 2.2 Million USD | 70.572% |
| Arrayit Corporation | 1.05 Million USD | 38.5% |
| Atlantic International Corp. | 236.49 Thousand USD | -174.5% |
| Biocept, Inc. | -788 Thousand USD | 182.384% |
| Bioqual, Inc. | -12 Million USD | 105.407% |
| CardioGenics Holdings Inc | 22.73 Thousand USD | -2754.928% |
| DermTech, Inc. | 17.65 Million USD | 96.323% |
| Global WholeHealth Partners Corporation | - USD | -Infinity% |
| Hangzhou Tigermed Consulting Co., Ltd. | -572.49 Million USD | 100.113% |
| HTG Molecular Diagnostics, Inc. | -7.37 Million USD | 108.8% |
| iMD Companies, Inc. | 1.11 Million USD | 41.825% |
| IDenta Corp. | 524.85 Thousand USD | -23.689% |
| Interpace Biosciences, Inc. | 7.69 Million USD | 91.562% |
| Integrative Health Technologies, Inc. | -26.95 Thousand USD | 2508.66% |
| InVitro International | -313.14 Thousand USD | 307.312% |
| Lumos Diagnostics Holdings Limited | 1.56 Million USD | 58.543% |
| Many Bright Ideas Technologies Inc. | -713.00 USD | 91149.369% |
| Medical Imaging Corp. | 3.79 Million USD | 82.875% |
| NovelStem International Corp. | 3.52 Million USD | 81.565% |
| Optigenex Inc. | 8.93 Million USD | 92.734% |
| PharmChem, Inc. | -1.49 Million USD | 143.441% |
| Proteome Sciences plc | 14.57 Million USD | 95.545% |
| Response Genetics, Inc | -13.08 Million USD | 104.961% |
| Rennova Health, Inc. | 14.82 Million USD | 95.622% |
| RushNet, Inc. | 4.8 Million USD | 86.478% |
| ScreenPro Security Inc. | 135.58 Thousand USD | -378.787% |
| Stella Diagnostics Inc. | 6.19 Million USD | 89.518% |
| StageZero Life Sciences Ltd. | 1.78 Million USD | 63.619% |
| Todos Medical Ltd. | 38.31 Million USD | 98.306% |